Efficacy and Safety of Tolvaptan in Subjects With Chronic Kidney Disease Between Late Stage 2 to Early Stage 4 Due to Autosomal Dominant Polycystic Kidney Disease

Authors
Category Primary study
Registry of Trialsclinicaltrials.gov
Year 2014
The purpose of the study is to determine whether tolvaptan is effective and safe for the treatment of late-stage chronic kidney disease due to autosomal dominant polycystic kidney disease (ADPKD)
Epistemonikos ID: f0e42e1016af45131e359714448f704a02a9cbd4
First added on: May 11, 2024